Clinical trial
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged…
NCT00150592 · Shire, Industry · Completed
Key facts
| NCT number | NCT00150592 |
|---|---|
| Title | Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17 |
| Official title | A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | SPD503 (Guanfacine HCl), Placebo |
| Enrollment | 182 |
| Start date | May 12, 2005 |
| Primary completion | Oct 5, 2005 |
| Completion | Oct 5, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 10, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: